- The FDA has approved the expanded use of Roche Holding AG’s (OTC:RHHBY) Xofluza (baloxavir marboxil).
- The medicine has been approved to treat acute uncomplicated influenza in otherwise healthy children aged 5-12 years who have shown symptoms for no more than 48 hours.
- This marks the first single-dose oral influenza medicine approved in the US for children in this age group.
- The FDA also approved Xofluza to prevent influenza in children aged five years to less than 12 years following contact with an infected person.
- Roche said Xofluza is already FDA-approved to treat influenza in people aged 12 and above.
- Price Action: RHHBY shares are up 1.71% at $41.74 during the market session on the last check Friday.
Why Accelerate Diagnostics (AXDX) Stock Is Down 38%
Accelerate Diagnostics shares are trading lower by 38% during Friday's session. The company priced an underwritten public offering of 6,860,659 units at $1.50 each.
